Ranolazine ( DrugBank: Ranolazine )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
58	肥大型心筋症	6
86	肺動脈性肺高血圧症	2
96	クローン病	1
113	筋ジストロフィー	1
114	非ジストロフィー性ミオトニー症候群	1

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03472950 (ClinicalTrials.gov)	June 11, 2018	1/3/2018	Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	ALS	Drug: Ranolazine 500 MG;Drug: Ranolazine 1000 MG	University of Kansas Medical Center	Gilead Sciences	Recruiting	18 Years	N/A	All	20	Phase 2	United States

58. 肥大型心筋症

臨床試験数 : 119 / 薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004402-42-IT (EUCTR)	06/10/2016	09/09/2021	A pilot study assessing the effects of Ranolazine on small heart vessels dysfunction in patients with hypertrophic cardiomyopathy	A pilot study assessing the effects of Ranolazine on coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy - Ranolazine microvascular dysfunction HCM	Hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1;Level: LLT;Classification code 10020204;Term: HOCM Hypertrophic obstructive cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10020203;Term: HOCM;Classification code 10020876;Term: Hypertrophic obstructive cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE Product Name: Ranolazina Ranexa Product Code: [C01EB18]	OSPEDALE SAN RAFFAELE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 2	Italy
2	NCT03953989 (ClinicalTrials.gov)	October 2016	13/5/2019	Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy	A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy	HCM - Hypertrophic Non-Obstructive Cardiomyopathy	Drug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die	IRCCS San Raffaele	Menarini International Operations Luxembourg SA	Completed	18 Years	80 Years	All	26	Phase 2	Italy
3	NCT01721967 (ClinicalTrials.gov)	November 2012	2/11/2012	Ranolazine for the Treatment of Chest Pain in HCM Patients	Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation	Hypertrophic Cardiomyopathy	Drug: Ranolazine	Duke University	Gilead Sciences	Completed	18 Years	N/A	All	14	Phase 4	United States
4	EUCTR2011-004507-20-DE (EUCTR)	02/07/2012	17/10/2011	SHCM	RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY) - RESTYLE- HCM STUDY	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 17.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE	Menarini International Operations Luxembourg S.A.	NULL	Not Recruiting			Female: yes Male: yes	100		Spain;Germany;Italy
5	EUCTR2011-004507-20-IT (EUCTR)	22/02/2012	08/03/2012	SHMC	RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: RANEXA60CPR 500MG R.P. INN or Proposed INN: RANOLAZINE Other descriptive name: NA Trade Name: RANEXA60CPR 750MG R.P. INN or Proposed INN: RANOLAZINE Other descriptive name: NA Trade Name: RANEXA INN or Proposed INN: RANOLAZINE Other descriptive name: NA	MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Spain;Germany;Italy
6	EUCTR2011-004507-20-ES (EUCTR)	19/01/2012	13/10/2011	SHMC	RANOLAZINE IN PATIENTS WITH SYMPTOMATICHYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDYASSESSING THE EFFECTS ON EXERCISE CAPACITY,DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE	Menarini International Operations Luxembourg S.A.	NULL	Not Recruiting			Female: yes Male: yes	100		Spain;Germany;Italy

先頭へ

86. 肺動脈性肺高血圧症

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01757808 (ClinicalTrials.gov)	August 2011	26/4/2012	A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension	A Phase I Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Ranolazine;Drug: Placebo	University of Chicago	NULL	Completed	18 Years	72 Years	All	12	Phase 1	United States
2	NCT01174173 (ClinicalTrials.gov)	June 2010	23/7/2010	Ranolazine and Pulmonary Hypertension	Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension	Angina;Pulmonary Arterial Hypertension	Drug: Ranolazine	Northwestern University	Gilead Sciences	Completed	18 Years	80 Years	All	11	Phase 3	United States

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04456517 (ClinicalTrials.gov)	March 1, 2022	29/6/2020	Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy	REACT Trial: A Randomized, Double Blind, Placebo-controlled, Crossover Study of Ranolazine for the Treatment of Crohn's Disease-associated Diarrhea	Crohn's Disease;Inflammatory Bowel Disease	Drug: Ranolazine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Enrolling by invitation	18 Years	N/A	All	16	Phase 2	United States

113. 筋ジストロフィー

臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02251457 (ClinicalTrials.gov)	August 2014	25/9/2014	Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1	Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1	Myotonia Congenita;Paramyotonia Congenita;Myotonic Dystrophy 1	Drug: Ranolazine	Ohio State University	Gilead Sciences	Completed	18 Years	100 Years	All	35	Phase 1	United States

114. 非ジストロフィー性ミオトニー症候群

臨床試験数 : 12 / 薬物数 : 19 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02251457 (ClinicalTrials.gov)	August 2014	25/9/2014	Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1	Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1	Myotonia Congenita;Paramyotonia Congenita;Myotonic Dystrophy 1	Drug: Ranolazine	Ohio State University	Gilead Sciences	Completed	18 Years	100 Years	All	35	Phase 1	United States

先頭へ